AM580
AM580 is a retinoic acid receptor agonist that is selective for RARα (Kd = 8 nM; AC50 = 0.36 nM) compared to RARβ (Kd = 131 nM; AC50 = 24.6 nM) and RARγ (Kd = 450 nM; AC50 = 27.9 nM).[1] It demonstrates greater specific binding to RARα compared to retinoic acid, which exhibits little selectivity across RARα, β, or γ.[1],[2],[3] AM580 has been used in combination with the GSK3β inhibitor CHIR99021 to efficiently induce differentiation of human induced pluripotent stem cells into immediate mesoderm.[4] It can also inhibit the proliferation of various tumor cells, inhibiting survival signaling pathways and inducing apoptosis.[5],[6]
102121-60-8
Item No.
TX0007U2
CAS No.
102121-60-8
Molecular Formula
C22H25NO3
Molecular Weight
351.4388
Pricing & Availability
Pack Size Purity Price(USD) Availability Quantity
1mg 98% $18.00 in stock
5mg >98.0%(HPLC) $50.00 in stock
10mg 95% $98.00 in stock
25mg 95% $164.00 in stock
50mg 95% $288.00 in stock
100mg >98.0%(HPLC) $403.00 in stock
500mg 95% $878.00 in stock
WARNING This product is for research use only. SDS
Technical Information
Item No.:
TX0007U2
Product Name:
AM580
Description:
Synonyms:
CD336; NSC 608001; Ro 40-6055; AM580
CAS Number:
102121-60-8
MDL:
MFCD00673916
Molecular Formula:
C22H25NO3
Molecular Weight:
351.4388
SMILES:
CC(CC1)(C)C2=C(C=CC(C(NC3=CC=C(C(O)=O)C=C3)=O)=C2)C1(C)C
λmax:
287 nm
In Vitro:
In the presence of G-CSF, AM580 (at 10-8 M) produces a remarkable induction in LAP mRNA of NB4 cells. At a concentration of 10-5 M, AM580 and ATRA, in combination with G-CSF, induce almost the same level of LAP transcript. AM580 (at 10-8 M) leads to an approximately sixfold increase in the steady-state levels of the transcript coding for the G-CSF receptor in NB4 cells AM580 (50 nM) increases caspase-3 expression in all of the colonies, and in 30% of the colonies induce acinar-like cavitation Knockdown of RARγ1 in primary Myc cells using shRARγ1 followed by Am580 treatment results in an even higher level of CRBP1 expression, showing that in these cells RARγ has a repressive effect on the RARα target gene CRBP1. Am580 (200 nM) enhances the anti-proliferative effect exhibited by RARγ knockdown in the MCF-10A and MCF-7 cell lines but not in the MDA-MB-231 cells. Method(s) not verified, for reference only.
In Vivo:
Am580 (0.3 mg/kg/day) treatment has a more profound effect on tumor-free survival of MMTV-wnt1 mice, the effect being noticeable even in early appearing tumors, and no overt toxicity is found in liver, lungs, kidney, and spleen. Am580 treatment reduces substantially and equally the level of hyperplasia in both transgenic glands. Treatment of MMTV-Myc mice with the RARα-selective agonist Am580 leads to significant inhibition of mammary tumor growth, lung metastasis and extends tumor latency in 63% of mice. Method(s) not verified, for reference only.
Kinase Assay:
MCF-10A (2×104) control cells or overexpressing RARγ are seeded in triplicates in 6-well culture dishes. After 24 hrs, cells are washed with PBS, incubated in 2 mL of DMEM-F12 culture medium, detached and counted every 24 hrs. Statistical significance is determined by t-test. pRB and p27 expression is tested by immunofluorescence analysis of control MCF-10A monolayers and monolayers stably transfected with pSG5-RARγ expression vector, using the same antibodies described for the IHC analysis.Method(s) not verified, for reference only., MCF-10A (2×104) control cells or overexpressing RARγ are seeded in triplicates in 6-well culture dishes. After 24 hrs, cells are washed with PBS, incubated in 2 mL of DMEM-F12 culture medium, detached and counted every 24 hrs. Statistical significance is determined by t-test. pRB and p27 expression is tested by immunofluorescence analysis of control MCF-10A monolayers and monolayers stably transfected with pSG5-RARγ expression vector, using the same antibodies described for the IHC analysis.*Method(s) not verified, for reference only.
Animal Administration:
Four months old uniparous (1 pregnancy/lactation cycle) MMTV-neu and 6 weeks old nulliparous MMTV-wnt1 female mice (50 mice/group) are treated with the RARα agonist AM580 (0.3 mg/kg body weight per mouse per day) in the diet (Purina 5053) by adding 1.5 mg AM580 per kg of Purina 5053 diet. Mice that develop tumors within the first month of treatment are removed from the study. Mice are palpated twice a week and tumor appearance is recorded. Once palpable, the size of the tumors is measured weekly. Tumor-free survival is calculated from Kaplan-Meier curves and statistical significance is determined by the Log-rank test for the survival studies and t-test for the tumor growth studies. Metastasis is evaluated by removing the lungs of all the anesthetized mice, selecting randomLy 20 mice per group and inspecting the lung surface for lesions using a stereoscope.Method(s) not verified, for reference only., Four months old uniparous (1 pregnancy/lactation cycle) MMTV-neu and 6 weeks old nulliparous MMTV-wnt1 female mice (50 mice/group) are treated with the RARα agonist AM580 (0.3 mg/kg body weight per mouse per day) in the diet (Purina 5053) by adding 1.5 mg AM580 per kg of Purina 5053 diet. Mice that develop tumors within the first month of treatment are removed from the study. Mice are palpated twice a week and tumor appearance is recorded. Once palpable, the size of the tumors is measured weekly. Tumor-free survival is calculated from Kaplan-Meier curves and statistical significance is determined by the Log-rank test for the survival studies and t-test for the tumor growth studies. Metastasis is evaluated by removing the lungs of all the anesthetized mice, selecting randomLy 20 mice per group and inspecting the lung surface for lesions using a stereoscope.*Method(s) not verified, for reference only.Approximately 1×106 NB4, HL-60, and APL fresh leukemic cells or CML neutrophils are harvested, pelletted by centrifugation at 400 g for 10 minutes, washed once with 0.9% NaCl, and centrifuged again. The washed cell pellet is resuspended in homogenization buffer (1 mM MgCl2, 1 mM CaCl2, 20 mM ZnCl2, 0.1 mM NaCl, 0.1% [vol/vol Triton X-100, 50 mM Tris/HCl, pH 7.4) and disrupted by vigorous pipetting. The homogenate is used for the LAP assay, which is performed with p-nitrophenol phosphate as substrate according to the instructions of the manufacturer. LAP activity is normalized for the content of protein in the sample. Proteins are measured according to the Bradford method using BSA fraction V as a standard. One unit of LAP activity is defined as the amount of enzyme capable of transforming 1 nmol of substrate in 1 minute at 25°C. Enzyme assays are performed in conditions of linearity relative to the substrate and to the concentration of proteins.Method(s) not verified, for reference only., Approximately 1×106 NB4, HL-60, and APL fresh leukemic cells or CML neutrophils are harvested, pelletted by centrifugation at 400 g for 10 minutes, washed once with 0.9% NaCl, and centrifuged again. The washed cell pellet is resuspended in homogenization buffer (1 mM MgCl2, 1 mM CaCl2, 20 mM ZnCl2, 0.1 mM NaCl, 0.1% [vol/vol] Triton X-100, 50 mM Tris/HCl, pH 7.4) and disrupted by vigorous pipetting. The homogenate is used for the LAP assay, which is performed with p-nitrophenol phosphate as substrate according to the instructions of the manufacturer. LAP activity is normalized for the content of protein in the sample. Proteins are measured according to the Bradford method using BSA fraction V as a standard. One unit of LAP activity is defined as the amount of enzyme capable of transforming 1 nmol of substrate in 1 minute at 25°C. Enzyme assays are performed in conditions of linearity relative to the substrate and to the concentration of proteins.*Method(s) not verified, for reference only.
Solubility:
DMF: 25 mg/ml, DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml, DMSO: 20 mg/ml, Ethanol: 10 mg/ml
Shipping Condition:
Room temperature in continental US; may vary elsewhere.
References & Citations:
[1]. 1.Kim, M.J., Ciletti, N., Michel, S., et al. The role of specific retinoid receptors in sebocyte growth and differentiation in culture J. Invest. Dermatol. 114(2),349-353 (2000).
[2]. Rochette-Egly, C., and Germain, P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs) Nucl. Recept. Signal 7,e005 (2009).
[3]. Bernard, B.A., Bernardon, J.-M., Delescluse, C., et al. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ Biochem. Biophys. Res. Commun. 186(2),977-983 (1992).
[4]. Araoka, T., Mae, S., Kurose, Y., et al. Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule-based differentiation methods PLoS One 9(1),e84881 (2014).
[5]. Cheng, Y.H., Utsunomiya, H., Pavone, M.E., et al. Retinoic acid inhibits endometrial cancer cell growth via multiple genomic mechanisms J. Mol. Endocrinol. 46(2),139-153 (2011).
[6]. Lu, Y., Bertran, S., Samuels, T.A., et al. Mechanism of inhibition of MMTV-neu and MMTV-wnt1 induced mammary oncogenesis by RARα agonist AM580 Oncogene 29(25),3665-3676 (2010).